Phylos is developing in vitro RNA-protein fusion technology for the rapid identification, selection and engineering of proteins (including antibodies) with unique characteristics. As this technology does not require the use of classical antibodies Or their components, we will investigate the targeting Of small protein scaffolds that may be more suitable for pharmacological use. Further, as we are able to select rare proteins from very large libraries (>10(l4) members), we expect to select binders with a much higher affinity (i.e. KD This technology will extend and improve the use of monoclonal antibody therapy for cancer. It will provide a means to identify more clinically useful protein targeting scaffolds and simultaneously speed the process of identifying high-affinity antigen binders. The identification of alternate scaffolds of defined and highly constrained structure for selection of antibody mimics will also be useful for small molecule drug design.Proposed Commercial Applications
